The ledger
Every compound, at a glance.
All 100 profiles in one place — what each is studied for, its class, and one plain evidence grade. Filter by name, class, or evidence; sort any column; expand a row for a quick read or open the full write-up.
| Compound | Class | Evidence |
|---|---|---|
| Anastrozole Medically: HR+ breast cancer in postmenopausal women (adjuvant, metastatic, and risk-reduction). Off-label/non-medical: used by men alongside steroids or TRT to suppress estrogen and raise testosterone. | Aromatase inhibitor | 10/10 · Established |
| What it isA selective, non-steroidal (Type II), reversible/competitive aromatase inhibitor (AI) that lowers estrogen by blocking the aromatase (CYP19A1) enzyme — not a steroid, not a SERM, and not a peptide. Also calledArimidex (originator AstraZeneca); now widely generic. Mainly studied forMedically: HR+ breast cancer in postmenopausal women (adjuvant, metastatic, and risk-reduction). Off-label/non-medical: used by men alongside steroids or TRT to suppress estrogen and raise testosterone. StatusUS prescription drug, NOT a controlled substance; prohibited at all times in sport under WADA S4.1 (aromatase inhibitors). Evidence10/10 · Established | ||
| Clomiphene Medically: ovulation induction in women. Off-label/PED-support: raising endogenous testosterone in hypogonadal men and restarting the HPG axis after steroid use. | SERM | 10/10 · Established |
| What it isA selective estrogen receptor modulator (SERM) of the triphenylethylene class — an oral, nonsteroidal ovulatory stimulant; not a peptide and not a steroid. Also calledClomid; clomiphene citrate; clomifene. A mix of two isomers — enclomiphene and zuclomiphene. Mainly studied forMedically: ovulation induction in women. Off-label/PED-support: raising endogenous testosterone in hypogonadal men and restarting the HPG axis after steroid use. StatusPrescription drug, not a controlled substance; prohibited at all times in sport (WADA S4.2, anti-estrogenic SERMs). Evidence10/10 · Established | ||
| Desmopressin Central diabetes insipidus, bedwetting, nocturia, and bleeding in mild hemophilia A and type 1 von Willebrand disease; promoted off-label as a memory enhancer. | Vasopressin analog | 10/10 · Established |
| What it isA synthetic structural analog of the hormone vasopressin (ADH); a selective V2-receptor agonist. Also calledDDAVP, dDAVP, 1-deamino-8-D-arginine vasopressin; brand names include DESMODA Mainly studied forCentral diabetes insipidus, bedwetting, nocturia, and bleeding in mild hemophilia A and type 1 von Willebrand disease; promoted off-label as a memory enhancer. StatusApproved prescription drug for decades (IV, subcutaneous, oral, sublingual, nasal); WADA-prohibited at all times as a masking agent. Evidence10/10 · Established | ||
| Exemestane Medically: ER-positive breast cancer in postmenopausal women (adjuvant and advanced disease), plus studied (not approved) for risk reduction. Off-label/illicit: estrogen suppression by anabolic-steroid users. | Aromatase inhibitor | 10/10 · Established |
| What it isAn oral, steroidal third-generation aromatase inhibitor (AI) — an irreversible 'suicide' inactivator of the aromatase (CYP19) enzyme. Not a peptide, not a SERM, not an anabolic steroid. Also calledAromasin (Pfizer; originally Pharmacia & Upjohn). Mainly studied forMedically: ER-positive breast cancer in postmenopausal women (adjuvant and advanced disease), plus studied (not approved) for risk reduction. Off-label/illicit: estrogen suppression by anabolic-steroid users. StatusUS prescription (Rx) drug — legal only with a valid prescription; NOT a controlled substance. Prohibited at all times in sport under WADA S4.1 (Aromatase Inhibitors). Evidence10/10 · Established | ||
| HCG Cryptorchidism, male hypogonadotropic hypogonadism, ovulation induction; off-label to preserve testicular function/fertility in androgen users and on TRT. | Gonadotropin | 10/10 · Established |
| What it isA glycoprotein hormone (a gonadotropin) that acts as a luteinizing-hormone analog — not a steroid and not an anabolic agent itself. Also calledPregnyl, Novarel (urinary); choriogonadotropin alfa / Ovidrel (recombinant); chorionic gonadotropin, CG. Mainly studied forCryptorchidism, male hypogonadotropic hypogonadism, ovulation induction; off-label to preserve testicular function/fertility in androgen users and on TRT. StatusPrescription drug, not a controlled substance; prohibited in sport (WADA S2) at all times in males only. Evidence10/10 · Established | ||
| Insulin Type 1 and advanced type 2 diabetes, gestational diabetes, diabetic ketoacidosis/hyperglycemic emergencies (medical); misused off-label for 'anabolic' muscle effects. | Peptide hormone | 10/10 · Established |
| What it isA 51-amino-acid peptide hormone (two disulfide-linked chains, ~5.8 kDa) — the body's primary anabolic and glucose-lowering hormone, secreted by pancreatic beta cells. Also calledRecombinant human insulin (Humulin, Novolin, ReliOn); analogs lispro, aspart, glulisine, glargine, detemir, degludec; forms regular, NPH, 70/30. Mainly studied forType 1 and advanced type 2 diabetes, gestational diabetes, diabetic ketoacidosis/hyperglycemic emergencies (medical); misused off-label for 'anabolic' muscle effects. StatusPrescription drug (older human insulins OTC via pharmacist in nearly all US states); NOT a controlled substance; prohibited at all times in sport under WADA S4.4.2. Evidence10/10 · Established | ||
| Letrozole Medically: HR-positive breast cancer in postmenopausal women (adjuvant, extended-adjuvant, and advanced disease), plus off-label ovulation induction in infertility/PCOS. Off-label/illicit: estrogen suppression by anabolic-steroid users. | Aromatase inhibitor | 10/10 · Established |
| What it isAn oral, nonsteroidal, reversible, competitive third-generation aromatase inhibitor (AI) — a triazole that blocks the aromatase (CYP19A1) enzyme. Not a peptide, not a SERM, not an anabolic steroid. Also calledFemara (Novartis). Mainly studied forMedically: HR-positive breast cancer in postmenopausal women (adjuvant, extended-adjuvant, and advanced disease), plus off-label ovulation induction in infertility/PCOS. Off-label/illicit: estrogen suppression by anabolic-steroid users. StatusUS prescription (Rx) drug — legal only with a valid prescription; NOT a controlled substance. Prohibited at all times in sport under WADA S4 (Hormone and Metabolic Modulators). Evidence10/10 · Established | ||
| Liothyronine Medically: hypothyroidism replacement, TSH suppression in thyroid cancer, thyroid suppression testing, myxedema coma. Off-label/illicit: a fat-loss / 'cutting' agent in bodybuilding. | Thyroid hormone | 10/10 · Established |
| What it isSynthetic L-triiodothyronine (T3) — the more biologically active of the two main thyroid hormones. A small-molecule hormone, not a peptide and not a steroid. Also calledT3; liothyronine sodium; brand name Cytomel (generics exist). Mainly studied forMedically: hypothyroidism replacement, TSH suppression in thyroid cancer, thyroid suppression testing, myxedema coma. Off-label/illicit: a fat-loss / 'cutting' agent in bodybuilding. StatusUS prescription (Rx-only) drug, NOT a DEA-controlled substance; NOT prohibited in sport by WADA, in or out of competition. Evidence10/10 · Established | ||
| Liraglutide Type 2 diabetes, chronic weight management, and cardiovascular risk reduction. | GLP-1 agonist | 10/10 · Established |
| What it isA once-daily injectable GLP-1 receptor agonist that lowers blood sugar and reduces appetite and body weight. Also calledNN2211; brands Victoza (diabetes) and Saxenda (obesity); part of Xultophy Mainly studied forType 2 diabetes, chronic weight management, and cardiovascular risk reduction. StatusFDA- and EMA-approved prescription drug; also sold gray-market as a research peptide. Evidence10/10 · Established | ||
| Oxytocin FDA-approved for labor and postpartum bleeding; researched off-label for autism and social/psychiatric conditions | Neuropeptide hormone | 10/10 · Established |
| What it isA naturally occurring 9-amino-acid peptide hormone made in the hypothalamus that drives uterine contraction and milk let-down and acts as a brain neuromodulator. Also calledPitocin, Syntocinon, "the love hormone"; chemically CYIQNCPLG-NH2 Mainly studied forFDA-approved for labor and postpartum bleeding; researched off-label for autism and social/psychiatric conditions StatusPrescription drug, FDA-approved as an injection only; no FDA-approved intranasal product Evidence10/10 · Established | ||
| PT-141 Low sexual desire and arousal — HSDD in women; also studied in erectile dysfunction. | Melanocortin | 10/10 · Established |
| What it isA synthetic cyclic seven-amino-acid peptide that activates melanocortin receptors (notably MC4R) in the brain. Also calledBremelanotide; Vyleesi Mainly studied forLow sexual desire and arousal — HSDD in women; also studied in erectile dysfunction. StatusFDA-approved as Vyleesi (2019) for premenopausal women with acquired, generalized HSDD. Evidence10/10 · Established | ||
| Raloxifene Medically: prevention and treatment of postmenopausal osteoporosis, and reduction of invasive breast-cancer risk in two postmenopausal populations. Off-label/illicit: estrogen-receptor blockade in breast tissue by male anabolic-steroid users (gynecomastia management, post-cycle attempts). | SERM | 10/10 · Established |
| What it isAn oral, once-daily selective estrogen receptor modulator (SERM) — a benzothiophene that acts as an estrogen agonist in bone and on lipids but an antagonist in breast and uterine tissue. Not a peptide, not an aromatase inhibitor, not an anabolic steroid. Also calledEvista (Eli Lilly); also available as generic raloxifene hydrochloride. Approved product is 60 mg once daily. Mainly studied forMedically: prevention and treatment of postmenopausal osteoporosis, and reduction of invasive breast-cancer risk in two postmenopausal populations. Off-label/illicit: estrogen-receptor blockade in breast tissue by male anabolic-steroid users (gynecomastia management, post-cycle attempts). StatusUS prescription (Rx) drug — legal only with a valid prescription; NOT a controlled substance. Prohibited at all times in sport under WADA S4.2 (anti-estrogenic substances). Evidence10/10 · Established | ||
| Semaglutide Type 2 diabetes, chronic weight management, and cardiovascular risk reduction. | GLP-1 agonist | 10/10 · Established |
| What it isA long-acting synthetic peptide that mimics the gut hormone GLP-1 (a GLP-1 receptor agonist). Also calledOzempic, Wegovy, Rybelsus; NN9535 Mainly studied forType 2 diabetes, chronic weight management, and cardiovascular risk reduction. StatusFDA-approved (Ozempic/Rybelsus for type 2 diabetes; Wegovy for weight management); also sold gray-market. Evidence10/10 · Established | ||
| Setmelanotide Rare melanocortin-pathway obesity: POMC/PCSK1 deficiency, LEPR deficiency, Bardet-Biedl syndrome, and acquired hypothalamic obesity. | Melanocortin | 10/10 · Established |
| What it isA synthetic cyclic 8-amino-acid peptide that mimics the appetite hormone alpha-MSH to switch on the brain's MC4 receptor. Also calledImcivree (brand); setmelanotide acetate; RM-493; BIM-22493; IRC-022493; CAS 920014-72-8 Mainly studied forRare melanocortin-pathway obesity: POMC/PCSK1 deficiency, LEPR deficiency, Bardet-Biedl syndrome, and acquired hypothalamic obesity. StatusFDA- and EMA-approved prescription orphan drug for specific rare conditions; not approved for common obesity or general weight loss. Evidence10/10 · Established | ||
| Somatropin Medical: GH deficiency and several pediatric/wasting conditions. Non-medical: marketed for anti-aging, fat loss, and athletic performance. | Growth hormone | 10/10 · Established |
| What it isRecombinant human growth hormone — a 191-amino-acid protein hormone, not a steroid and not a peptide-class research chemical. Also calledrhGH, HGH, somatropin; brands include Humatrope, Nutropin, Genotropin, Norditropin, Saizen, Omnitrope, Serostim, Zorbtive. Mainly studied forMedical: GH deficiency and several pediatric/wasting conditions. Non-medical: marketed for anti-aging, fat loss, and athletic performance. StatusPrescription drug; not a controlled substance but governed by its own felony statute (21 U.S.C. § 333(e)); banned at all times in sport (WADA S2). Evidence10/10 · Established | ||
| Tamoxifen Medically: ER-positive breast cancer (treatment, adjuvant, and risk reduction) and DCIS; off-label gynecomastia. In the PED context: blunting estrogen-driven side effects from anabolic steroids and attempting post-cycle testosterone restart. | SERM | 10/10 · Established |
| What it isA nonsteroidal triphenylethylene-derivative selective estrogen receptor modulator (SERM) — it blocks the estrogen receptor in some tissues and weakly activates it in others. Not a peptide, not an aromatase inhibitor, not an anabolic steroid. Also calledNolvadex (and generics); marketed as the citrate salt. Originally developed by ICI (later AstraZeneca) as compound ICI 46,474. Mainly studied forMedically: ER-positive breast cancer (treatment, adjuvant, and risk reduction) and DCIS; off-label gynecomastia. In the PED context: blunting estrogen-driven side effects from anabolic steroids and attempting post-cycle testosterone restart. StatusUS prescription (Rx) drug — legal only with a valid prescription; NOT a controlled substance. Prohibited at all times in sport under WADA S4.2 (anti-estrogens / SERMs). Evidence10/10 · Established | ||
| Testosterone Medical: replacement therapy in confirmed male hypogonadism (and delayed puberty in boys). Non-medical: off-label use to increase lean mass, strength, and recovery. | Anabolic steroid | 10/10 · Established |
| What it isThe principal endogenous human androgen — a C19 steroid (4-androsten-17β-ol-3-one) and the prototypical anabolic-androgenic steroid (AAS); not a peptide. Also calledBrand names include AndroGel (transdermal gel), Jatenzo (oral testosterone undecanoate); injectable esters such as testosterone enanthate, cypionate, and undecanoate; the 17α-alkylated oral methyltestosterone. Mainly studied forMedical: replacement therapy in confirmed male hypogonadism (and delayed puberty in boys). Non-medical: off-label use to increase lean mass, strength, and recovery. StatusFDA-approved prescription drug (hypogonadism only); DEA Schedule III controlled substance; prohibited at all times in sport under WADA category S1 (Anabolic Agents). Evidence10/10 · Established | ||
| Tirzepatide Type 2 diabetes, chronic weight management, and obstructive sleep apnea. | GLP-1 agonist | 10/10 · Established |
| What it isA synthetic peptide that activates two gut-hormone receptors at once (a GIP and GLP-1 dual agonist). Also calledMounjaro, Zepbound; LY3298176; "twincretin" Mainly studied forType 2 diabetes, chronic weight management, and obstructive sleep apnea. StatusFDA-approved (Mounjaro for type 2 diabetes; Zepbound for weight management and sleep apnea); also sold gray-market. Evidence10/10 · Established | ||
| Afamelanotide Preventing phototoxicity in adults with erythropoietic protoporphyria (EPP) | Melanocortin | 9/10 · Strong |
| What it isA synthetic, longer-acting analog of the body's own α-melanocyte-stimulating hormone that switches on the skin's pigment machinery. Also calledMelanotan-1; MT-1; NDP-α-MSH; [Nle⁴,D-Phe⁷]-α-MSH; CUV1647; brand name Scenesse Mainly studied forPreventing phototoxicity in adults with erythropoietic protoporphyria (EPP) StatusPrescription orphan drug; EU authorisation 2014, FDA approval 2019; clinician-implanted only Evidence9/10 · Strong | ||
| CagriSema Chronic weight management in obesity or overweight with a weight-related comorbidity, with and without type 2 diabetes | GLP-1 agonist | 9/10 · Strong |
| What it isA once-weekly injectable fixed combination of cagrilintide (an amylin analog) and semaglutide 2.4 mg (a GLP-1 receptor agonist), studied for weight loss. Also calledCagrilintide 2.4 mg / semaglutide 2.4 mg; Novo Nordisk Mainly studied forChronic weight management in obesity or overweight with a weight-related comorbidity, with and without type 2 diabetes StatusNot approved anywhere as of June 2026; NDA submitted to the FDA in December 2025. Not banned in sport (semaglutide is on WADA's Monitoring Program). Evidence9/10 · Strong | ||
| Methandrostenolone Historically prescribed (osteoporosis, growth deficiency); now used non-medically for muscle/strength/weight gain. | Anabolic steroid | 9/10 · Strong |
| What it isA synthetic oral anabolic-androgenic steroid (AAS) derived from testosterone — not a peptide. Also calledMetandienone, methandienone, Dianabol, 'Dbol' Mainly studied forHistorically prescribed (osteoporosis, growth deficiency); now used non-medically for muscle/strength/weight gain. StatusUS Schedule III controlled substance with no current FDA approval; prohibited at all times in sport (WADA S1.1). Evidence9/10 · Strong | ||
| Orforglipron Chronic weight management (approved) and type 2 diabetes (Phase 3, not yet approved). | GLP-1 agonist | 9/10 · Strong |
| What it isAn oral, non-peptide small-molecule GLP-1 receptor agonist (an incretin-pathway drug taken as a daily pill). Also calledBrand name Foundayo (Eli Lilly); development codes LY3502970 and OWL-833 (originally discovered by Chugai Pharmaceutical). Mainly studied forChronic weight management (approved) and type 2 diabetes (Phase 3, not yet approved). StatusFDA-approved April 1, 2026 for chronic weight management; not yet approved for type 2 diabetes. Carries a boxed warning. Its GLP-1 drug class is monitored — not prohibited — by WADA. Evidence9/10 · Strong | ||
| Oxymetholone Medical: anemias of deficient red-cell production (FDA label) and investigationally HIV-associated wasting and hemodialysis muscle/insulin outcomes. Non-medical: bodybuilding mass and strength (illicit doping). | Anabolic steroid | 9/10 · Strong |
| What it isA synthetic anabolic-androgenic steroid — a 17α-alkylated, orally active derivative of dihydrotestosterone (DHT). It is a steroid, not a peptide. Also calledAnadrol-50; older trade name Anapolon; chemically 2-hydroxymethylene-17α-methyl-DHT. Mainly studied forMedical: anemias of deficient red-cell production (FDA label) and investigationally HIV-associated wasting and hemodialysis muscle/insulin outcomes. Non-medical: bodybuilding mass and strength (illicit doping). StatusFDA-approved prescription drug; DEA Schedule III controlled substance; prohibited at all times in sport (WADA S1.1). Evidence9/10 · Strong | ||
| Drostanolone Historically: palliative hormonal treatment of metastatic breast cancer. In fitness use: 'hardening,' 'dryness,' and strength — none of which have controlled human evidence. | Anabolic steroid | 8/10 · Good |
| What it isA synthetic anabolic-androgenic steroid (AAS) of the dihydrotestosterone (DHT) family — 2α-methyl-DHT, given as injectable esters. Not a peptide, not a SARM. Also calledMasteron; dromostanolone (USAN); drostanolone propionate; historic brands Drolban, Masteril, Masterid, Metormon, Permastril. Mainly studied forHistorically: palliative hormonal treatment of metastatic breast cancer. In fitness use: 'hardening,' 'dryness,' and strength — none of which have controlled human evidence. StatusNo current FDA-approved indication; DEA Schedule III controlled substance; prohibited at all times in sport (WADA S1.1). Evidence8/10 · Good | ||
| Enclomiphene Medically (off-label/investigational): raising endogenous testosterone in men with secondary hypogonadism while preserving fertility. In the PED context: restarting endogenous testosterone after steroid use and countering estrogenic side effects. | SERM | 8/10 · Good |
| What it isAn oral, nonsteroidal selective estrogen receptor modulator (SERM) — the (E)-/trans-isomer of clomiphene, acting as an estrogen-receptor antagonist at the hypothalamus and pituitary. Not a peptide and not a steroid. Also calledEnclomifene (INN); tentative brand names Androxal (US) and EnCyzix (EU). It is the predominantly anti-estrogenic isomer of clomiphene citrate (Clomid). Mainly studied forMedically (off-label/investigational): raising endogenous testosterone in men with secondary hypogonadism while preserving fertility. In the PED context: restarting endogenous testosterone after steroid use and countering estrogenic side effects. StatusNOT FDA-approved for any use; investigational, Rx-only via compounding; not a controlled substance. Prohibited at all times in sport (WADA S4.2, anti-estrogenic SERMs). Evidence8/10 · Good | ||
| Fluoxymesterone Medical (largely historical): male hypogonadism and delayed puberty, and palliation of androgen-responsive metastatic breast cancer in women. Non-medical (illicit): strength, aggression/'drive,' and a hard/dry look in bodybuilding. | Anabolic steroid | 8/10 · Good |
| What it isA synthetic anabolic-androgenic steroid (AAS) — a 17α-methylated, orally active derivative of testosterone. It is a steroid, not a peptide and not a SARM. Also calledHalotestin; generic Androxy (both discontinued in the US); chemically 9-fluoro-17α-methyl-11β,17β-dihydroxyandrost-4-en-3-one (C20H29FO3). Mainly studied forMedical (largely historical): male hypogonadism and delayed puberty, and palliation of androgen-responsive metastatic breast cancer in women. Non-medical (illicit): strength, aggression/'drive,' and a hard/dry look in bodybuilding. StatusFDA-approved molecule but brand and generic discontinued in the US; DEA Schedule III controlled substance; prohibited at all times in sport (WADA S1.1). Evidence8/10 · Good | ||
| Methenolone Medically: aplastic/refractory anemia and (historically) advanced breast cancer. Off-label/illicit: physique and 'lean mass' use among athletes. | Anabolic steroid | 8/10 · Good |
| What it isA synthetic anabolic-androgenic steroid (AAS) derived from dihydrotestosterone (DHT) — not a peptide. Also calledMetenolone (INN); brands Primobolan, Primobolan Depot, Nibal, Nibal Depot; acetate (oral) and enanthate (injectable) esters. Mainly studied forMedically: aplastic/refractory anemia and (historically) advanced breast cancer. Off-label/illicit: physique and 'lean mass' use among athletes. StatusUS Schedule III controlled substance (no FDA-approved product); banned at all times in sport under WADA S1 anabolic agents. Evidence8/10 · Good | ||
| Nandrolone Medical: anemia of renal insufficiency, and studied for HIV/dialysis-associated wasting. Non-medical: lean-mass and 'joint comfort' adjunct in bodybuilding. | Anabolic steroid | 8/10 · Good |
| What it isA synthetic anabolic-androgenic steroid (AAS) — 19-nortestosterone, the C19-demethylated analogue of testosterone. It is not a peptide and not a SARM. Also calledDeca-Durabolin (nandrolone decanoate); Durabolin (nandrolone phenylpropionate); '19-nor'; colloquially 'Deca.' Mainly studied forMedical: anemia of renal insufficiency, and studied for HIV/dialysis-associated wasting. Non-medical: lean-mass and 'joint comfort' adjunct in bodybuilding. StatusDEA Schedule III controlled substance, prescription-only in the US; prohibited at all times in sport (WADA S1.1). Evidence8/10 · Good | ||
| Oxandrolone Catabolic-illness recovery: severe burns, HIV/AIDS-associated wasting, and short stature in Turner syndrome (as an adjunct to growth hormone). | Anabolic steroid | 8/10 · Good |
| What it isA synthetic anabolic-androgenic steroid; a 17α-alkylated, orally active derivative of dihydrotestosterone (DHT) — not a SARM and not a peptide. Also calledAnavar; brand name Oxandrin (originally Searle/BTG). Mainly studied forCatabolic-illness recovery: severe burns, HIV/AIDS-associated wasting, and short stature in Turner syndrome (as an adjunct to growth hormone). StatusPrescription drug; DEA Schedule III controlled substance; prohibited at all times in sport (WADA S1.1a). Evidence8/10 · Good | ||
| Sermorelin Diagnosing and treating growth hormone deficiency; marketed off-label for anti-aging and GH support. | GH secretagogue | 8/10 · Good |
| What it isA synthetic peptide made of the first 29 amino acids of growth-hormone-releasing hormone (a GHRH analog). Also calledGRF 1-29, GHRH(1-29); Geref Mainly studied forDiagnosing and treating growth hormone deficiency; marketed off-label for anti-aging and GH support. StatusFormerly FDA-approved (Geref, discontinued 2008); now only via compounding pharmacies and the gray market. Evidence8/10 · Good | ||
| Stanozolol Medically: hereditary angioedema prophylaxis and some anemias historically. In sport/bodybuilding: lean-mass retention, strength, and a 'dry/hard' look. | Anabolic steroid | 8/10 · Good |
| What it isA synthetic anabolic-androgenic steroid (AAS) derived from dihydrotestosterone (DHT), 17α-alkylated and orally active — not a peptide and not a SARM. Also calledWinstrol; Winstrol Depot (injectable aqueous suspension). Mainly studied forMedically: hereditary angioedema prophylaxis and some anemias historically. In sport/bodybuilding: lean-mass retention, strength, and a 'dry/hard' look. StatusDEA Schedule III controlled substance; no longer marketed in the US; prohibited at all times in sport (WADA S1.1, anabolic androgenic steroids). Evidence8/10 · Good | ||
| Tesamorelin Reducing excess visceral (abdominal) fat in HIV-associated lipodystrophy; studied for cognition and fatty liver. | GH secretagogue | 8/10 · Good |
| What it isA synthetic analog of growth-hormone-releasing hormone (GHRH), stabilized with an added chemical group. Also calledEgrifta, Egrifta SV, Egrifta WR; TH9507 Mainly studied forReducing excess visceral (abdominal) fat in HIV-associated lipodystrophy; studied for cognition and fatty liver. StatusFDA-approved as Egrifta (2010) for excess abdominal fat in HIV-related lipodystrophy — the only GHRH analog with US approval. Evidence8/10 · Good | ||
| Thymosin Alpha-1 Immune modulation; chronic hepatitis B and C; adjunct in some cancers and infections. | Immune peptide | 8/10 · Good |
| What it isA naturally occurring 28-amino-acid peptide (a fragment of the protein prothymosin alpha) that helps regulate the immune system. Also calledThymalfasin; Zadaxin; Tα1 Mainly studied forImmune modulation; chronic hepatitis B and C; adjunct in some cancers and infections. StatusNot FDA-approved; approved and marketed in many other countries (e.g., as Zadaxin) for hepatitis B/C and immune indications. Evidence8/10 · Good | ||
| AOD-9604 Originally obesity and fat loss; later promoted for fat metabolism and joint/cartilage support. | Fat-loss peptide | 7/10 · Moderate |
| What it isA synthetic fragment of human growth hormone (the C-terminal region, residues 176-191, plus an added tyrosine) — not the full hormone. Also calledAOD9604; hGH fragment 176-191 (modified) Mainly studied forOriginally obesity and fat loss; later promoted for fat metabolism and joint/cartilage support. StatusFailed as an obesity drug and not FDA-approved as a medicine; promoted as a food ingredient under GRAS claims; banned in sport (WADA). Evidence7/10 · Moderate | ||
| Cagrilintide Chronic weight management in overweight/obesity, with and without type 2 diabetes | Amylin analog | 7/10 · Moderate |
| What it isAn investigational once-weekly synthetic analog of the gut/pancreatic hormone amylin, studied for weight loss alone and combined with semaglutide as CagriSema. Also calledAM833; NN9838; NNC0174-0833; component of CagriSema; CAS 1415456-99-3 Mainly studied forChronic weight management in overweight/obesity, with and without type 2 diabetes StatusNot approved anywhere as of June 2026; CagriSema NDA submitted to FDA December 2025 Evidence7/10 · Moderate | ||
| Cardarine Dyslipidemia and metabolic disease (clinically); endurance and fat loss (in marketing claims) | PPARδ agonist | 7/10 · Moderate |
| What it isA synthetic small-molecule PPARδ (peroxisome proliferator-activated receptor delta) agonist — not a peptide and not a SARM. Also calledGW1516, Endurobol, Cardarine Mainly studied forDyslipidemia and metabolic disease (clinically); endurance and fat loss (in marketing claims) StatusNever approved for human or veterinary use; development halted ~2007 over cancer findings; banned in sport at all times (WADA S4.5). Evidence7/10 · Moderate | ||
| Clenbuterol Bronchodilation (asthma abroad; airway obstruction in horses); used off-label/illicitly for fat loss and lean-mass preservation, and illegally as a livestock growth promoter. | Beta-2 agonist | 7/10 · Moderate |
| What it isA long-acting, selective beta-2 adrenergic receptor agonist (a small-molecule sympathomimetic bronchodilator) — not a steroid, not an androgen, and not a peptide. Also calledClenbuterol HCl; brand names Spiropent (human, some countries) and Ventipulmin (veterinary, equine). Mainly studied forBronchodilation (asthma abroad; airway obstruction in horses); used off-label/illicitly for fat loss and lean-mass preservation, and illegally as a livestock growth promoter. StatusNo US human FDA approval (veterinary-only by prescription); NOT a controlled substance; prohibited at all times in sport under WADA S1.2 (Other Anabolic Agents). Evidence7/10 · Moderate | ||
| Ecnoglutide Glycemic control in type 2 diabetes and chronic weight management in overweight/obesity. | GLP-1 agonist | 7/10 · Moderate |
| What it isA once-weekly injectable peptide GLP-1 receptor agonist, engineered to be 'cAMP-biased,' developed for type 2 diabetes and weight management. Also calledXW003; developed by Hangzhou Sciwind Biosciences; partnered with Pfizer China for Chinese commercialization Mainly studied forGlycemic control in type 2 diabetes and chronic weight management in overweight/obesity. StatusApproved in China only (2026); not FDA-approved. GLP-1 agonists are on the WADA Monitoring Program (watched, not banned). Evidence7/10 · Moderate | ||
| Gonadorelin Diagnostic pituitary testing; pulsatile-pump induction of ovulation and spermatogenesis in GnRH-deficient patients. | Reproductive peptide | 7/10 · Moderate |
| What it isA synthetic peptide identical to natural gonadotropin-releasing hormone (GnRH), the brain signal that tells the pituitary to release LH and FSH. Also calledGnRH, LHRH, LH-RH; brands Factrel, Lutrepulse/Lutrelef; veterinary Fertagyl, Cystorelin Mainly studied forDiagnostic pituitary testing; pulsatile-pump induction of ovulation and spermatogenesis in GnRH-deficient patients. StatusFormerly FDA-approved (Factrel, Lutrepulse), both human products commercially withdrawn; US human use is now via compounding pharmacies only. Evidence7/10 · Moderate | ||
| Kisspeptin-10 Acutely raising LH, FSH and testosterone; probing the reproductive hormone axis | Reproductive peptide | 7/10 · Moderate |
| What it isA 10-amino-acid peptide that switches on reproductive hormone release by stimulating GnRH neurons in the brain. Also calledKp-10; KP-10; residues 45–54 of kisspeptin-54 Mainly studied forAcutely raising LH, FSH and testosterone; probing the reproductive hormone axis StatusNot approved anywhere; investigational and gray-market only Evidence7/10 · Moderate | ||
| Ligandrol Muscle wasting/cachexia, age-related sarcopenia, and post-hip-fracture recovery; used illicitly for muscle gain and recomposition. | SARM | 7/10 · Moderate |
| What it isA nonsteroidal selective androgen receptor modulator (SARM) — a small molecule that binds the androgen receptor, not a peptide. Also calledLGD-4033, Ligandrol, VK5211 (Viking Therapeutics development code) Mainly studied forMuscle wasting/cachexia, age-related sarcopenia, and post-hip-fracture recovery; used illicitly for muscle gain and recomposition. StatusNot FDA-approved for any use; not a lawful supplement ingredient; prohibited at all times in sport (WADA S1.2). Evidence7/10 · Moderate | ||
| Mazdutide Chronic weight management and type 2 diabetes; exploratory liver-fat work. | GLP-1 agonist | 7/10 · Moderate |
| What it isA once-weekly injectable peptide that activates two gut-hormone receptors at once (GLP-1 and glucagon) to drive weight loss and lower blood sugar. Also calledIBI362; LY3305677; OXM3; CAS 2259884-03-0; generic Chinese name 玛仕度肽 (mǎshìdùtài) Mainly studied forChronic weight management and type 2 diabetes; exploratory liver-fat work. StatusApproved in China (2025); investigational and not FDA-approved elsewhere. Evidence7/10 · Moderate | ||
| Methylene Blue Methemoglobinemia (approved); investigational use in vasoplegic/septic shock and ifosfamide-induced encephalopathy; popularly claimed for cognition, energy, and longevity | Redox agent | 7/10 · Moderate |
| What it isA synthetic phenothiazine dye that acts as a small-molecule reduction-oxidation (redox) agent — not a peptide and not a hormone/SARM. Also calledMethylthioninium chloride; ProvayBlue (FDA-approved injection); methylene blue injection (older products) Mainly studied forMethemoglobinemia (approved); investigational use in vasoplegic/septic shock and ifosfamide-induced encephalopathy; popularly claimed for cognition, energy, and longevity StatusFDA-approved prescription drug for methemoglobinemia; not a DEA-controlled substance; not on the WADA Prohibited List Evidence7/10 · Moderate | ||
| MK-677 Growth hormone deficiency; historically frailty, hip-fracture recovery, Alzheimer's, obesity, sleep | GH secretagogue | 7/10 · Moderate |
| What it isAn orally active, non-peptide small molecule that mimics ghrelin to make the body release more growth hormone. Also calledIbutamoren; ibutamoren mesylate; MK-0677; L-163,191; LUM-201; former tentative brand "Oratrope" Mainly studied forGrowth hormone deficiency; historically frailty, hip-fracture recovery, Alzheimer's, obesity, sleep StatusInvestigational only; never FDA-approved; banned in sport by WADA at all times. Evidence7/10 · Moderate | ||
| Ostarine Muscle wasting / cancer cachexia and, more recently, AR-positive advanced breast cancer (investigational) | SARM | 7/10 · Moderate |
| What it isA non-steroidal, orally active selective androgen receptor modulator (SARM) — a small synthetic molecule, not a peptide. Also calledMK-2866, GTx-024, S-22; international nonproprietary name enobosarm (developed by GTx, Inc., later Veru Inc.) Mainly studied forMuscle wasting / cancer cachexia and, more recently, AR-positive advanced breast cancer (investigational) StatusNot approved by FDA or EMA for any use; prohibited at all times in sport under WADA category S1.2 Evidence7/10 · Moderate | ||
| Retatrutide Obesity, type 2 diabetes, and fatty liver disease (MASH). | GLP-1 agonist | 7/10 · Moderate |
| What it isAn investigational synthetic peptide that activates three hormone receptors at once (a GIP, GLP-1, and glucagon triple agonist). Also calledLY3437943 Mainly studied forObesity, type 2 diabetes, and fatty liver disease (MASH). StatusInvestigational; not approved for any use (in Phase 3 trials as of 2026). Evidence7/10 · Moderate | ||
| Survodutide Obesity, MASH (fatty liver disease) with fibrosis, and type 2 diabetes. | GLP-1 agonist | 7/10 · Moderate |
| What it isAn investigational once-weekly injectable peptide that activates both the glucagon and GLP-1 receptors, being developed for obesity and fatty-liver disease. Also calledBI 456906; CAS 2805997-46-8 — no approved brand name Mainly studied forObesity, MASH (fatty liver disease) with fibrosis, and type 2 diabetes. StatusInvestigational; not approved by any regulator (in Phase 3 trials as of 2026). Evidence7/10 · Moderate | ||
| Tesofensine Obesity/weight loss (its main investigational use); also studied as Tesomet for hypothalamic obesity and Prader-Willi syndrome; originally trialed for Parkinson's/Alzheimer's disease. | Weight-loss drug | 7/10 · Moderate |
| What it isA small-molecule oral triple monoamine reuptake inhibitor (blocks reuptake of noradrenaline, dopamine, and serotonin), from the phenyltropane chemical family — NOT a peptide and not a hormone. Also calledNS2330; developed by NeuroSearch, later Saniona; Tesomet is the fixed-dose tesofensine + metoprolol combination. Mainly studied forObesity/weight loss (its main investigational use); also studied as Tesomet for hypothalamic obesity and Prader-Willi syndrome; originally trialed for Parkinson's/Alzheimer's disease. StatusInvestigational everywhere; NOT approved by the FDA, EMA, or (as of mid-2026) COFEPRIS in Mexico. Prohibited in-competition as a stimulant under WADA S6 (2025 list). Evidence7/10 · Moderate | ||
| VK2735 Obesity/overweight and metabolic disease (weight management); not a muscle-building agent | GLP-1 agonist | 7/10 · Moderate |
| What it isAn investigational dual agonist of the GLP-1 and GIP receptors (the same incretin receptor class as tirzepatide), in subcutaneous and oral forms. Also calledVK2735; developed by Viking Therapeutics; subcutaneous program VANQUISH, oral program VENTURE-Oral Mainly studied forObesity/overweight and metabolic disease (weight management); not a muscle-building agent StatusInvestigational only — not approved anywhere. Subcutaneous form in Phase 3; oral form completed Phase 2. Not on the WADA Prohibited List. Evidence7/10 · Moderate | ||
| Amycretin Overweight/obesity and type 2 diabetes | GLP-1 agonist | 6/10 · Preliminary |
| What it isAn investigational unimolecular (single-molecule) peptide that activates both the GLP-1 receptor and the amylin receptor, in oral and injectable forms. Also calledNovo Nordisk's 'first-in-class GLP-1 and amylin receptor agonist' Mainly studied forOverweight/obesity and type 2 diabetes StatusNot approved anywhere as of mid-2026; Phase 3 obesity program planned to initiate Q1 2026; GLP-1 class is on the WADA Monitoring Program, not prohibited. Evidence6/10 · Preliminary | ||
| Cerebrolysin Acute ischemic stroke, vascular dementia, Alzheimer's disease, traumatic brain injury | Nootropic peptide | 6/10 · Preliminary |
| What it isAn injectable mixture of low-molecular-weight peptides and free amino acids made by enzymatically breaking down purified pig brain protein. Also calledFPF-1070; Cerebrolysin Ebewe; Cerebrolyzin; Renacenz; CAS 12656-61-0 Mainly studied forAcute ischemic stroke, vascular dementia, Alzheimer's disease, traumatic brain injury StatusNot FDA-approved or legally sold in the US; prescription drug in several Eastern European, Asian and Latin American countries Evidence6/10 · Preliminary | ||
| CJC-1295 Originally GH deficiency and muscle wasting; sold to raise GH and IGF-1. | GH secretagogue | 6/10 · Preliminary |
| What it isA synthetic, modified GHRH(1-29) peptide; the DAC version is engineered to bind albumin for a much longer half-life. Also calledDAC:GRF, CJC-1295 with DAC; no-DAC form = Modified GRF 1-29 ("mod GRF 1-29") Mainly studied forOriginally GH deficiency and muscle wasting; sold to raise GH and IGF-1. StatusNever approved; an abandoned drug candidate sold gray-market as "research use only"; banned in sport (WADA). Evidence6/10 · Preliminary | ||
| Follistatin 344 Muscle-wasting disease (Becker and Duchenne muscular dystrophy, inclusion body myositis) via gene therapy; marketed gray-market for muscle growth and fat loss with no supporting human data. | Myostatin inhibitor | 6/10 · Preliminary |
| What it isA follistatin protein (the 344-amino-acid isoform) that antagonizes myostatin and activin — a myostatin/activin-pathway inhibitor, not a small peptide. Also calledFS344; huFollistatin344; trial gene-therapy construct rAAV1.CMV.huFollistatin344 (also written AAV1.CMV.FS344) Mainly studied forMuscle-wasting disease (Becker and Duchenne muscular dystrophy, inclusion body myositis) via gene therapy; marketed gray-market for muscle growth and fat loss with no supporting human data. StatusNot approved by any regulator for any use; legitimate human work reached only early-phase (Phase 1 / Phase 1/2) gene-therapy trials; WADA-prohibited at all times (S4.3). Evidence6/10 · Preliminary | ||
| GHRP-2 Diagnostic provocation of growth hormone secretion; investigationally for GH deficiency and appetite | GH secretagogue | 6/10 · Preliminary |
| What it isA synthetic six-amino-acid peptide that mimics the hunger hormone ghrelin to make the pituitary release a pulse of growth hormone. Also calledPralmorelin; growth hormone-releasing peptide-2; KP-102; GPA-748; brand "GHRP Kaken" (Japan) Mainly studied forDiagnostic provocation of growth hormone secretion; investigationally for GH deficiency and appetite StatusNot FDA-approved in the US; approved in Japan only as a diagnostic; banned by WADA Evidence6/10 · Preliminary | ||
| GHRP-6 Growth-hormone release and GH-deficiency testing; small Cuban trials in heart attack and stroke; used gray-market for muscle, fat loss, and appetite. | GH secretagogue | 6/10 · Preliminary |
| What it isA synthetic six-amino-acid peptide that mimics ghrelin to trigger a pulse of growth hormone and a strong surge of hunger. Also calledSKF-110679; growth hormone-releasing hexapeptide; developed clinically in Cuba as CIGB-500 Mainly studied forGrowth-hormone release and GH-deficiency testing; small Cuban trials in heart attack and stroke; used gray-market for muscle, fat loss, and appetite. StatusNot approved for human use anywhere; prohibited in sport; sold gray-market as "research use only." Evidence6/10 · Preliminary | ||
| Glutathione Raising body glutathione stores; investigated in Parkinson's disease and fatty liver; popularly marketed (especially as IV drips) for skin lightening, anti-aging, detox, recovery, and performance | Antioxidant | 6/10 · Preliminary |
| What it isAn endogenous tripeptide (gamma-L-glutamyl-L-cysteinyl-glycine) that is the body's principal intracellular antioxidant and redox buffer — a true peptide, not a hormone or SARM. Also calledGSH, reduced glutathione, L-glutathione, gamma-glutamylcysteinylglycine Mainly studied forRaising body glutathione stores; investigated in Parkinson's disease and fatty liver; popularly marketed (especially as IV drips) for skin lightening, anti-aging, detox, recovery, and performance StatusNot an FDA-approved drug for any wellness/cosmetic use; sold as a supplement/cosmetic ingredient and as compounded (not FDA-approved) injectables. Not a controlled substance. Glutathione itself is not WADA-prohibited, but large-volume IV infusion is restricted. Evidence6/10 · Preliminary | ||
| Hexarelin Diagnosing and treating growth-hormone deficiency; later cardiac effects; marketed gray-market for muscle, fat loss, recovery, and anti-aging. | GH secretagogue | 6/10 · Preliminary |
| What it isA synthetic six-amino-acid peptide that mimics ghrelin to trigger a burst of growth-hormone release from the pituitary. Also calledExamorelin (INN); developmental codes EP-23905 and MF-6003; a member of the GH-releasing peptide (GHRP) family. Mainly studied forDiagnosing and treating growth-hormone deficiency; later cardiac effects; marketed gray-market for muscle, fat loss, recovery, and anti-aging. StatusNever approved by any regulator; development stalled at Phase II. Banned at all times in sport by WADA. Evidence6/10 · Preliminary | ||
| Ipamorelin Growth-hormone release; investigated for gut-motility disorders; marketed gray-market for anti-aging and bodybuilding. | GH secretagogue | 6/10 · Preliminary |
| What it isA synthetic pentapeptide (five amino acids) that mimics ghrelin to stimulate growth-hormone release. Also calledNNC 26-0161 Mainly studied forGrowth-hormone release; investigated for gut-motility disorders; marketed gray-market for anti-aging and bodybuilding. StatusNot approved for human use anywhere; sold gray-market as "research use only." Evidence6/10 · Preliminary | ||
| Melanotan II Skin tanning (melanogenesis); sexual arousal and erectile function in early research. | Melanocortin | 6/10 · Preliminary |
| What it isA synthetic cyclic analog of the natural hormone alpha-melanocyte-stimulating hormone (α-MSH). Also calledMelanotan II, MT-II, MT-2 Mainly studied forSkin tanning (melanogenesis); sexual arousal and erectile function in early research. StatusNot approved for human use in any country; sold gray-market as "research use only"; multiple health agencies have warned against it. Evidence6/10 · Preliminary | ||
| NMN Raising cellular NAD+, with claimed downstream effects on aging, metabolism, exercise capacity, and cardiovascular/cognitive function. | NAD+ precursor | 6/10 · Preliminary |
| What it isA small-molecule nucleotide (nicotinamide joined to a ribose-phosphate) that is a direct biosynthetic precursor to NAD+ — not a peptide, SARM, or steroid. Also calledβ-Nicotinamide mononucleotide, beta-NMN, NMN Mainly studied forRaising cellular NAD+, with claimed downstream effects on aging, metabolism, exercise capacity, and cardiovascular/cognitive function. StatusNot FDA-approved as a drug; its dietary-supplement legality is disputed in the US. Not a controlled substance and not on the WADA Prohibited List. Evidence6/10 · Preliminary | ||
| Selank Anxiety, stress, and cognitive or nootropic effects. | Nootropic peptide | 6/10 · Preliminary |
| What it isA synthetic heptapeptide (seven amino acids) based on the natural immune-regulating peptide tuftsin. Also calledTP-7; sequence TKPRPGP Mainly studied forAnxiety, stress, and cognitive or nootropic effects. StatusReportedly registered in Russia (~2009) as an intranasal anxiolytic; not approved in the US or most countries. Evidence6/10 · Preliminary | ||
| Semax Stroke recovery, cognitive and memory disorders, neuroprotection; nootropic use. | Nootropic peptide | 6/10 · Preliminary |
| What it isA synthetic heptapeptide analog of a fragment (positions 4-10) of the hormone ACTH, without its steroid-stimulating activity. Also calledACTH(4-10) analog; sequence MEHFPGP Mainly studied forStroke recovery, cognitive and memory disorders, neuroprotection; nootropic use. StatusPrescription drug in Russia (and Ukraine); on Russia's Vital & Essential Drugs list; not approved in the US or most countries. Evidence6/10 · Preliminary | ||
| SS-31 Barth syndrome (approved), primary mitochondrial myopathy, dry AMD/geographic atrophy, heart failure, acute MI. | Mitochondrial peptide | 6/10 · Preliminary |
| What it isA synthetic mitochondria-targeting tetrapeptide that binds and stabilizes cardiolipin in the inner mitochondrial membrane to support energy production. Also calledElamipretide; MTP-131; Bendavia (cardiac-trial era); FORZINITY (FDA-approved brand); D-Arg-Dmt-Lys-Phe-NH2 Mainly studied forBarth syndrome (approved), primary mitochondrial myopathy, dry AMD/geographic atrophy, heart failure, acute MI. StatusFDA accelerated approval (Sept 2025) for muscle strength in Barth syndrome only; everything else is off-label or unapproved. Evidence6/10 · Preliminary | ||
| Thymosin Beta-4 Corneal/eye-surface healing, dry eye, and wound repair; cardiac and stroke repair (preclinical, abandoned). | Healing peptide | 6/10 · Preliminary |
| What it isA naturally occurring 43-amino-acid protein found in nearly all human cells whose main job is binding the cell's actin building blocks. Also calledTβ4; TB4; timbetasin (WHO INN); RGN-259, RGN-352, RGN-137 (drug codes) — not the same as TB-500 Mainly studied forCorneal/eye-surface healing, dry eye, and wound repair; cardiac and stroke repair (preclinical, abandoned). StatusNot approved anywhere; holds FDA orphan-drug designation for neurotrophic keratopathy (2013); banned in sport by WADA. Evidence6/10 · Preliminary | ||
| ARA-290 Small-fiber neuropathy in sarcoidosis; diabetic neuropathy; diabetic macular edema | Tissue-protective peptide | 5/10 · Early |
| What it isA synthetic 11-amino-acid peptide copied from one surface of erythropoietin, designed to protect and repair tissue without making red blood cells. Also calledCibinetide (INN); ARA-290; helix-B surface peptide (HBSP/pHBSP); no approved brand name Mainly studied forSmall-fiber neuropathy in sarcoidosis; diabetic neuropathy; diabetic macular edema StatusInvestigational only — not approved anywhere; holds orphan/fast-track designations (development incentives, not approvals) Evidence5/10 · Early | ||
| Argireline Reducing the appearance of dynamic facial wrinkles (crow's feet, forehead and frown lines) when applied to the skin. | Cosmetic peptide | 5/10 · Early |
| What it isA synthetic six–amino-acid peptide applied topically in anti-aging cosmetics, designed to blunt the nerve signaling that drives facial-muscle contraction. Also calledAcetyl hexapeptide-8; acetyl hexapeptide-8 amide; acetyl hexapeptide-3 (older INCI name); Argireline (Lipotec/Lubrizol trademark); Ac-EEMQRR-NH2; CAS 616204-22-9 Mainly studied forReducing the appearance of dynamic facial wrinkles (crow's feet, forehead and frown lines) when applied to the skin. StatusNot an approved drug anywhere; sold worldwide as an over-the-counter cosmetic ingredient. Evidence5/10 · Early | ||
| DSIP Sleep regulation; exploratory work on stress, pain, and withdrawal — though its true function remains unclear. | Sleep peptide | 5/10 · Early |
| What it isA naturally occurring nine-amino-acid neuropeptide (sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu). Also calledDelta sleep-inducing peptide Mainly studied forSleep regulation; exploratory work on stress, pain, and withdrawal — though its true function remains unclear. StatusNot an approved drug anywhere; exists only as an experimental research compound and gray-market peptide. Evidence5/10 · Early | ||
| Epitalon Aging and longevity research, telomerase activation, and pineal/melatonin function (mostly cell and animal studies). | Longevity peptide | 5/10 · Early |
| What it isA synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) modeled on a natural pineal-gland substance. Also calledEpithalon, Epithalone Mainly studied forAging and longevity research, telomerase activation, and pineal/melatonin function (mostly cell and animal studies). StatusNot approved in the US or EU (research compound only); in Russia the related pineal extract epithalamin has seen gerontology use. Evidence5/10 · Early | ||
| GHK-Cu Wound healing, skin repair, collagen stimulation, anti-aging and hair-care cosmetics. | Cosmetic peptide | 5/10 · Early |
| What it isA naturally occurring small peptide (the tripeptide glycyl-L-histidyl-L-lysine) bound to a copper ion. Also calledCopper tripeptide-1, GHK-copper, Cu-GHK Mainly studied forWound healing, skin repair, collagen stimulation, anti-aging and hair-care cosmetics. StatusNot a drug; widely used as a cosmetic ingredient ("copper peptide") and sold as a research or cosmetic compound. Evidence5/10 · Early | ||
| LL-37 Topical chronic-wound healing; intratumoral immuno-oncology; broad preclinical immune defense | Antimicrobial peptide | 5/10 · Early |
| What it isLL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino-acid host-defense molecule the body makes naturally. Also calledCathelicidin (CAMP gene product); hCAP18/LL-37; developmental drug name ropocamptide Mainly studied forTopical chronic-wound healing; intratumoral immuno-oncology; broad preclinical immune defense StatusEndogenous human peptide; not FDA-approved anywhere; most advanced trial failed its primary endpoint Evidence5/10 · Early | ||
| Thymalin Immune/thymic restoration (T-cell maturation, normalizing CD4/CD8/NK populations); also studied for geroprotection and respiratory illness in the elderly. | Immune peptide | 5/10 · Early |
| What it isA polypeptide complex extracted from calf (bovine) thymus gland — a mixture, not a single defined molecule — from the Russian 'Khavinson bioregulator' / cytomedine tradition. Also calledThymalinum; short active peptides isolated from it include KE/Vilon (Lys-Glu), EW/Thymogen (Glu-Trp), and EDP/Crystagen (Glu-Asp-Pro). Mainly studied forImmune/thymic restoration (T-cell maturation, normalizing CD4/CD8/NK populations); also studied for geroprotection and respiratory illness in the elderly. StatusApproved in Russia since 1982 (a national registration, lower bar than a US NDA); not FDA-approved and never reviewed by the FDA — sold in the US only as a 'research chemical, not for human use.' Treat as high-risk / presumptively prohibited for athletes. Evidence5/10 · Early | ||
| VIP Inflammatory and respiratory disease (ARDS, COVID-19 respiratory failure, sarcoidosis, pulmonary hypertension) and — in online protocols — intranasal use for 'CIRS' and neuroinflammation. | Neuropeptide | 5/10 · Early |
| What it isA naturally occurring 28-amino-acid neuropeptide of the secretin/glucagon family; the synthetic drug form is aviptadil. Also calledAviptadil (synthetic VIP); brand/formulation ZYESAMI / RLF-100 Mainly studied forInflammatory and respiratory disease (ARDS, COVID-19 respiratory failure, sarcoidosis, pulmonary hypertension) and — in online protocols — intranasal use for 'CIRS' and neuroinflammation. StatusNo VIP product is FDA-approved for any indication; aviptadil is investigational (FDA declined emergency authorization twice). Intranasal CIRS use is compounded, off-label material. Anti-doping status likely captured by WADA S2 catch-all (verify per athlete). Evidence5/10 · Early | ||
| BPC-157 Tissue and wound healing, tendon and gut repair, and anti-inflammatory effects — almost entirely in animals. | Healing peptide | 4/10 · Animal-leaning |
| What it isA synthetic 15-amino-acid peptide (a pentadecapeptide) based on a fragment of a protein reported in gastric juice. Also calledBody Protection Compound-157; PL 14736 Mainly studied forTissue and wound healing, tendon and gut repair, and anti-inflammatory effects — almost entirely in animals. StatusNot approved for human use; sold gray-market as "research use only." A US FDA advisory committee is slated to review its compounding in 2026. Evidence4/10 · Animal-leaning | ||
| TB-500 Tissue repair, wound healing, and recovery — mainly in animal and veterinary work. | Healing peptide | 4/10 · Animal-leaning |
| What it isA synthetic copy of the active region of thymosin beta-4 — the 7-amino-acid fragment Ac-LKKTETQ, not the full protein. Also calledThymosin beta-4 fragment 17-23 (often conflated with full-length thymosin beta-4) Mainly studied forTissue repair, wound healing, and recovery — mainly in animal and veterinary work. StatusNot approved for human use; banned by WADA; encountered as a designer drug in racehorses. Evidence4/10 · Animal-leaning | ||
| 5-Amino-1MQ Obesity, fat loss, metabolic dysfunction (insulin sensitivity, hepatic steatosis), and muscle/aging — all in preclinical models. | NNMT inhibitor | 3/10 · Animal only |
| What it isA small-molecule, cell-permeable inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT) — a methylquinolinium chemical, NOT a peptide, SARM, or steroid. Also called5-amino-1-methylquinolinium; 5A1MQ; 5-amino-1MQ (commonly supplied as the iodide salt) Mainly studied forObesity, fat loss, metabolic dysfunction (insulin sensitivity, hepatic steatosis), and muscle/aging — all in preclinical models. StatusPreclinical/research-grade only. Not FDA-approved, not a dietary supplement, not on the FDA 503A compounding list. No verifiable completed human trial. Not specifically named on the WADA 2026 Prohibited List. Evidence3/10 · Animal only | ||
| Adipotide Obesity and fat reduction — investigated in obese mice and monkeys, with a single first-in-human Phase 1 in obese patients with metastatic prostate cancer. | Fat-loss peptide | 3/10 · Animal only |
| What it isA synthetic chimeric peptidomimetic that homes to the blood vessels supplying white fat and triggers apoptosis there — a vascular-targeting cytotoxic, not a hormone or appetite drug. Also calledFTPP; Prohibitin Targeting Peptide 1 (clinical trial title); Prohibitin-TP01 (Arrowhead); 'PTP-1' is informal shorthand, not an official designation Mainly studied forObesity and fat reduction — investigated in obese mice and monkeys, with a single first-in-human Phase 1 in obese patients with metastatic prostate cancer. StatusNot approved anywhere; no marketed product; no active clinical development verifiable as of mid-2026. Sold only as research-grade ('not for human use') material. Evidence3/10 · Animal only | ||
| Andarine Muscle wasting/cachexia, osteoporosis, and benign prostatic hyperplasia (preclinical and early-stage only). | SARM | 3/10 · Animal only |
| What it isA synthetic non-steroidal small molecule (arylpropionamide-class selective androgen receptor modulator) — not a peptide. Also calledS-4, GTx-007 / GTX-007 Mainly studied forMuscle wasting/cachexia, osteoporosis, and benign prostatic hyperplasia (preclinical and early-stage only). StatusNot FDA-approved for any use; not a lawful supplement ingredient; prohibited at all times in sport (WADA category S1.2). Evidence3/10 · Animal only | ||
| Boldenone FDA-approved only as a veterinary drug for debilitated horses; used non-medically (off-label/illicit) in humans for lean mass, strength, appetite, and red-cell stimulation. | Anabolic steroid | 3/10 · Animal only |
| What it isA synthetic injectable anabolic-androgenic steroid (1-dehydrotestosterone); not 17α-alkylated, used as the long-acting undecylenate ester. Not a peptide and not a SARM. Also calledEquipoise (veterinary); boldenone undecylenate; the discontinued human product Parenabol; informally 'EQ'. Mainly studied forFDA-approved only as a veterinary drug for debilitated horses; used non-medically (off-label/illicit) in humans for lean mass, strength, appetite, and red-cell stimulation. StatusUS: Schedule III controlled substance (specifically named at 21 U.S.C. § 802(41)); no human FDA approval. Sport: prohibited at all times (WADA S1.1). Evidence3/10 · Animal only | ||
| Dihexa Synaptogenesis and cognition in animal models; promoted online as a nootropic. | Nootropic peptide | 3/10 · Animal only |
| What it isA synthetic oligopeptide derived from angiotensin IV, engineered for better stability, oral absorption, and brain penetration. Also calledPNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide; CAS 1401708-83-5 Mainly studied forSynaptogenesis and cognition in animal models; promoted online as a nootropic. StatusResearch-grade only; no human trials, no FDA approval; prohibited in sport at all times under WADA category S0. Evidence3/10 · Animal only | ||
| GW-0742 Preclinical metabolic, cardiovascular, and endurance research; marketed (without support) as an 'exercise mimetic' | PPARδ agonist | 3/10 · Animal only |
| What it isA synthetic small-molecule agonist of PPARδ (peroxisome proliferator-activated receptor delta) — not a peptide and not a SARM. Also calledGW0742, GW610742, GW-0742X, GW610742X (CAS 317318-84-6) Mainly studied forPreclinical metabolic, cardiovascular, and endurance research; marketed (without support) as an 'exercise mimetic' StatusResearch-grade chemical only — never approved for any use, no clinical development program; prohibited at all times in sport under WADA S4. Evidence3/10 · Animal only | ||
| Humanin Cytoprotection, neuroprotection and amyloid toxicity, cognitive aging, and lifespan/healthspan — almost entirely in cells and animals. | Mitochondrial peptide | 3/10 · Animal only |
| What it isA 24-amino-acid mitochondrial-derived peptide (MDP) — the first one discovered — encoded within the mitochondrial 16S rRNA region (MT-RNR2). Also calledMT-RNR2 peptide; HN; the synthetic analog HNG (S14G-humanin) is used in most preclinical work. Mainly studied forCytoprotection, neuroprotection and amyloid toxicity, cognitive aging, and lifespan/healthspan — almost entirely in cells and animals. StatusNot approved anywhere for any indication; research-grade only. Not named on the WADA list, but high-risk under the open S0/S2 classes — treat as likely prohibited in sport. Evidence3/10 · Animal only | ||
| IGF-1 DES Muscle and tissue growth in animals and cell culture; no studied human use for weight loss, muscle, or metabolic disease. | Growth factor | 3/10 · Animal only |
| What it isA truncated, naturally occurring variant of the human protein hormone insulin-like growth factor 1 (IGF-1), missing its first three amino acids. Also calleddes(1-3)IGF-I, DES(1-3), des(1-3)-IGF-1 Mainly studied forMuscle and tissue growth in animals and cell culture; no studied human use for weight loss, muscle, or metabolic disease. StatusNot approved as a drug anywhere; sold as a "research use only" chemical; prohibited at all times in sport (WADA S2). Evidence3/10 · Animal only | ||
| IGF-1 LR3 Mainly a cell-culture reagent (bioproduction); also studied for muscle and tissue growth in animals. | Growth factor (IGF-1) | 3/10 · Animal only |
| What it isA lab-modified, longer-lasting version of the human protein hormone insulin-like growth factor 1 (IGF-1). Also calledLong R3 IGF-1, Long Arg3 IGF-1, LR3-IGF-I Mainly studied forMainly a cell-culture reagent (bioproduction); also studied for muscle and tissue growth in animals. StatusNot approved as a human drug; sold as a "research use only" reagent and used gray-market in bodybuilding. Evidence3/10 · Animal only | ||
| KPV Intestinal and skin inflammation and wound healing — all preclinical. | Anti-inflammatory peptide | 3/10 · Animal only |
| What it isThe C-terminal tripeptide of alpha-MSH (lysine-proline-valine) that carries much of the parent hormone's anti-inflammatory activity. Also calledLys-Pro-Val; alpha-MSH(11–13) Mainly studied forIntestinal and skin inflammation and wound healing — all preclinical. StatusNot approved for any use; sold gray-market as a research peptide. A US FDA advisory committee is slated to review its compounding in July 2026. Evidence3/10 · Animal only | ||
| LGD-3303 Investigated conceptually for osteoporosis/frailty in rodents; marketed (unproven) for muscle gain and recomposition. | SARM | 3/10 · Animal only |
| What it isA nonsteroidal selective androgen receptor modulator (SARM) — a small molecule that binds the androgen receptor, not a peptide. Also calledLGD-3303; CAS 917891-35-1 (C16H14ClF3N2O) Mainly studied forInvestigated conceptually for osteoporosis/frailty in rodents; marketed (unproven) for muscle gain and recomposition. StatusNot approved by any regulator for human or veterinary use; not a lawful supplement ingredient; prohibited at all times in sport (WADA S1.2). Evidence3/10 · Animal only | ||
| Methasterone No approved medical use; used illicitly for lean-mass gain, strength, and 'recomposition.' | Anabolic steroid | 3/10 · Animal only |
| What it isA synthetic, orally active anabolic-androgenic steroid (AAS) — a 17α-alkylated derivative of dihydrotestosterone (essentially drostanolone with an added 17α-methyl group); not a peptide and not a SARM. Also calledMethyldrostanolone, methasteron; designer-supplement trade name Superdrol (CAS 3381-88-2). Mainly studied forNo approved medical use; used illicitly for lean-mass gain, strength, and 'recomposition.' StatusDEA Schedule III controlled anabolic steroid (US); prohibited at all times in sport (WADA S1.1, Anabolic Androgenic Steroids). Evidence3/10 · Animal only | ||
| MGF Local muscle repair and satellite-cell activation; explored in animals for neurogenesis and motoneuron rescue. No approved use. | Growth factor | 3/10 · Animal only |
| What it isAn alternative-splice variant of the IGF-1 gene (IGF-1Ec) whose unique C-terminal E-peptide is proposed to act as a local muscle-repair signal; PEG-MGF is a synthetic, PEGylated research-chemical version. Also calledIGF-1Ec (human) / IGF-1Eb (rodent), MGF E-peptide, PEG-MGF (PEGylated form) Mainly studied forLocal muscle repair and satellite-cell activation; explored in animals for neurogenesis and motoneuron rescue. No approved use. StatusResearch-grade / preclinical; not approved anywhere; prohibited at all times in sport (WADA S2). Evidence3/10 · Animal only | ||
| MOTS-c Glucose and metabolic regulation, insulin sensitivity, obesity, exercise mimicry, and aging (mostly preclinical). | Mitochondrial peptide | 3/10 · Animal only |
| What it isA small (16-amino-acid) mitochondrial-derived peptide — encoded within mitochondrial DNA rather than the cell nucleus. Also calledEncoded in the MT-RNR1 (12S rRNA) gene Mainly studied forGlucose and metabolic regulation, insulin sensitivity, obesity, exercise mimicry, and aging (mostly preclinical). StatusNot approved for any medical use; banned in sport by WADA (2024); sold gray-market as "research use only." Evidence3/10 · Animal only | ||
| S23 Originally a male hormonal contraceptive candidate; marketed (unproven) for lean mass and recomposition | SARM | 3/10 · Animal only |
| What it isA nonsteroidal aryl-propanamide selective androgen receptor modulator (SARM) — a small synthetic molecule, not a peptide. Also calledMastorin; S-23; CAS 1010396-29-8 (C18H13ClF4N2O3) Mainly studied forOriginally a male hormonal contraceptive candidate; marketed (unproven) for lean mass and recomposition StatusNot an approved drug and not a lawful supplement ingredient; not federally scheduled, but prohibited at all times in sport by WADA. Evidence3/10 · Animal only | ||
| SLU-PP-332 Endurance/exercise capacity and metabolic disease in preclinical (mouse) models; marketed without support as an 'exercise mimetic' for endurance and fat loss | Exercise mimetic | 3/10 · Animal only |
| What it isA synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα/β/γ) — a hydrazide-class compound (CAS 303760-60-3), not a peptide. Also calledSLU-PP-332; orally active follow-up analog SLU-PP-915 Mainly studied forEndurance/exercise capacity and metabolic disease in preclinical (mouse) models; marketed without support as an 'exercise mimetic' for endurance and fat loss StatusPreclinical research-grade only; no human trials; not approved as a drug, supplement, or cosmetic anywhere. Not named on the WADA 2026 list, but anti-doping labs are developing detection methods. Evidence3/10 · Animal only | ||
| Stenabolic Circadian and metabolic disorders in preclinical models; marketed (without support) as an endurance and fat-loss 'exercise mimetic' | REV-ERB agonist | 3/10 · Animal only |
| What it isA synthetic small-molecule agonist of the REV-ERB nuclear receptors (a circadian/metabolic transcriptional repressor) — not a peptide, not a hormone, not a true androgen-receptor SARM. Also calledStenabolic, SR9009 Mainly studied forCircadian and metabolic disorders in preclinical models; marketed (without support) as an endurance and fat-loss 'exercise mimetic' StatusUnapproved investigational drug, not a legal supplement; prohibited at all times in sport (WADA S4) Evidence3/10 · Animal only | ||
| Testolone Originally developed for AR-positive/ER-positive breast cancer; marketed online for muscle building. | SARM | 3/10 · Animal only |
| What it isA non-steroidal selective androgen receptor modulator (SARM); a small molecule, not a peptide. Also calledRAD-140, RAD140, Testolone Mainly studied forOriginally developed for AR-positive/ER-positive breast cancer; marketed online for muscle building. StatusNot FDA-approved and not a lawful supplement ingredient; prohibited at all times in sport (WADA S1.2). Evidence3/10 · Animal only | ||
| Trenbolone No validated human use; historically marketed in France for muscle-wasting/cachexia, and approved in the US only as a growth-promoting cattle implant. Used non-medically for muscle and strength. | Anabolic steroid | 3/10 · Animal only |
| What it isA synthetic anabolic-androgenic steroid (AAS) — a 19-nortestosterone (nandrolone) derivative used as injectable esters; not a SARM and not a peptide. Also calledParabolan and Hexabolan (the discontinued human hexahydrobenzylcarbonate ester); cattle implants include Finaplix-H, Revalor, and Synovex; common esters are trenbolone acetate and trenbolone enanthate. Mainly studied forNo validated human use; historically marketed in France for muscle-wasting/cachexia, and approved in the US only as a growth-promoting cattle implant. Used non-medically for muscle and strength. StatusNever FDA-approved for human use; DEA Schedule III controlled substance; prohibited at all times in sport (WADA S1.1). Evidence3/10 · Animal only | ||
| Turinabol Used historically as an East German prescription anabolic agent; later infamous as a performance/doping agent, most notably in the GDR state doping program. | Anabolic steroid | 3/10 · Animal only |
| What it isAn orally active 17α-alkylated anabolic-androgenic steroid; the 4-chloro derivative of metandienone (Dianabol). Not a peptide and not a SARM. Also calledChlorodehydromethyltestosterone / dehydrochloromethyltestosterone (CDMT, DHCMT); 4-chlorodehydromethyltestosterone; Oral Turinabol; 'Tbol.' Mainly studied forUsed historically as an East German prescription anabolic agent; later infamous as a performance/doping agent, most notably in the GDR state doping program. StatusNever FDA-approved in the US; a Schedule III controlled substance as an anabolic steroid; prohibited at all times in sport (WADA S1.1). Evidence3/10 · Animal only | ||
| YK-11 Marketed for muscle growth, strength, and recomposition; studied only in cell and animal models. | SARM | 3/10 · Animal only |
| What it isA synthetic steroidal selective androgen receptor modulator (SARM) — a gem-dimethyl/dienone derivative on a 19-norandrostane backbone (C25H34O6, CAS 1370003-76-1); not a peptide. Also calledYK11; sold through 'research chemical' / SARM channels; sometimes labeled a 'myostatin-inhibiting SARM.' Mainly studied forMarketed for muscle growth, strength, and recomposition; studied only in cell and animal models. StatusNot an approved drug or lawful supplement (FDA classifies SARMs as unapproved drugs); not federally scheduled; prohibited at all times in sport (WADA S1.2). Evidence3/10 · Animal only | ||
| AICAR Cardioprotection in bypass surgery and relapsed/refractory CLL (clinically; both stalled); endurance, fat loss and 'longevity' (in marketing only) | Exercise mimetic | 1/10 · Unsupported |
| What it isA small-molecule purine nucleoside analog (an AICA-riboside) that activates AMP-activated protein kinase (AMPK) — not a peptide, not a hormone, not a SARM. Also calledAcadesine, AICA-riboside, AICA ribonucleotide; proposed oncology trade name 'Acadra'; CAS 2627-69-2 Mainly studied forCardioprotection in bypass surgery and relapsed/refractory CLL (clinically; both stalled); endurance, fat loss and 'longevity' (in marketing only) StatusNever approved anywhere; sold as a research chemical 'not for human consumption'; prohibited at all times in sport (WADA S4.4.1, AMPK activators). Evidence1/10 · Unsupported | ||
| DNP Historically (1930s) an over-the-counter weight-loss agent; today no legitimate human use. A controlled-release analog (MP101) has been studied investigationally for neurodegenerative disease. Misused illicitly for aggressive fat loss in bodybuilding. | Mitochondrial uncoupler | 1/10 · Unsupported |
| What it isA small synthetic aromatic compound (a substituted phenol) that acts as a chemical uncoupler of oxidative phosphorylation — not a peptide, not a hormone, and not a steroid. Also called2,4-Dinitrophenol; 2,4-DNP; Dinitrophenol; historically marketed in the 1930s as a slimming agent. Mainly studied forHistorically (1930s) an over-the-counter weight-loss agent; today no legitimate human use. A controlled-release analog (MP101) has been studied investigationally for neurodegenerative disease. Misused illicitly for aggressive fat loss in bodybuilding. StatusNever FDA-approved for human consumption; illegal to sell for human use (and prosecuted) in the US; NOT a controlled substance; NOT specifically named on the WADA Prohibited List. Evidence1/10 · Unsupported | ||
| Mesterolone Medically (outside the US): male hypogonadism/androgen deficiency and, more controversially, idiopathic male infertility. Off-label/illicit: claimed 'anti-estrogen,' 'free-testosterone,' libido, and 'hardening' effects in physique use. | Anabolic steroid | 1/10 · Unsupported |
| What it isA synthetic, orally active anabolic-androgenic steroid (AAS) derived from dihydrotestosterone (DHT) — 1α-methyl-DHT. Not a peptide, not a SARM. Also calledProviron; mesterolone (INN); chemically 1α-methyl-5α-androstan-17β-ol-3-one. Mainly studied forMedically (outside the US): male hypogonadism/androgen deficiency and, more controversially, idiopathic male infertility. Off-label/illicit: claimed 'anti-estrogen,' 'free-testosterone,' libido, and 'hardening' effects in physique use. StatusNever FDA-approved or marketed in the US; still a US Schedule III controlled substance as an anabolic steroid; prohibited at all times in sport (WADA S1). Evidence1/10 · Unsupported | ||
| SNAP-8 Reducing the appearance of dynamic (expression) facial wrinkles when applied to the skin. | Cosmetic peptide | 1/10 · Unsupported |
| What it isA synthetic eight–amino-acid peptide applied topically in anti-aging cosmetics, designed to blunt the nerve signaling that drives facial-muscle contraction. Also calledAcetyl octapeptide-3; SNAP-8 (Lipotec/Lubrizol trade name); an extended analog of Argireline (Acetyl Hexapeptide-8); PubChem CID 71587832 Mainly studied forReducing the appearance of dynamic (expression) facial wrinkles when applied to the skin. StatusNot an approved drug; sold as an over-the-counter cosmetic ingredient (EU INCI listed). Not on the WADA Prohibited List. Evidence1/10 · Unsupported | ||
| Turkesterone Marketed for muscle growth, strength, and recovery as a 'natural anabolic.' | Ecdysteroid | 1/10 · Unsupported |
| What it isAn ecdysteroid (phytoecdysteroid) — a polyhydroxylated plant/insect steroid; not a peptide and not a SARM. Also calledAjuga turkestanica extract; sold alongside related ecdysteroids like 20-hydroxyecdysone (ecdysterone, 20E). Mainly studied forMarketed for muscle growth, strength, and recovery as a 'natural anabolic.' StatusNot FDA-approved; sold as a dietary-supplement ingredient. Not DEA-controlled. Not WADA-prohibited (related ecdysterone is monitored, not banned). Evidence1/10 · Unsupported | ||
No compounds match — .